Caitlyn
(Amrubicin)Phase 3Small molecule
Bristol-Myers SquibbAmrubicin is a chemotherapy drug used to treat certain types of lung cancer, particularly small cell lung cancer. It works by damaging cancer cell DNA to stop the cancer cells from growing and dividing.[1] Caitlyn is currently being investigated across 1 indication[3], with its most advanced program in Phase 3.[1]
Caitlyn is one of 5 small molecule programs targeting Extensive Stage Small Cell Lung Cancer (ES-SCLC). It is currently in Phase 3.
1
Indications
19
Total Trials
4
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Extensive Stage Small Cell Lung Cancer (ES-SCLC)
#DrugCompanyPhaseTrials
1TRODELVY
GileadPhase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Trodelvy
GileadPhase 3
Hycamtin
MMeitheal
Phase 3
Caitlyn
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer9 trials
Show 6 more trials
Breast Cancer2 trials
Multiple Myeloma1 trial
Urothelial Carcinoma1 trial
5 more indications
Soft Tissue Sarcoma1 trial
Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Amrubicin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- DNA Topoisomerase II Alpha Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company